AU2001289641A1 - Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses - Google Patents
Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnessesInfo
- Publication number
- AU2001289641A1 AU2001289641A1 AU2001289641A AU8964101A AU2001289641A1 AU 2001289641 A1 AU2001289641 A1 AU 2001289641A1 AU 2001289641 A AU2001289641 A AU 2001289641A AU 8964101 A AU8964101 A AU 8964101A AU 2001289641 A1 AU2001289641 A1 AU 2001289641A1
- Authority
- AU
- Australia
- Prior art keywords
- fragments
- derivatives
- illnesses
- producing
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000000541 Defensins Human genes 0.000 title abstract 2
- 108010002069 Defensins Proteins 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 abstract 1
- 241000191940 Staphylococcus Species 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 238000009792 diffusion process Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Peptides (I) of the defensin type, are new. New peptides (I) have formula (F1). ZN-C-X m-X 1-X-C-X 2-X n-C-X-X-X-X 3-XO-C-X p-C-C-ZC (F1) ZN and ZC : 1 - 30 amino acid (aa) residues; X : any aa; X many 3 - 6 aa; X n2 - 3 aa; X o5 - 9 aa; X p4 - 6 aa; X 1G, A or P; X 2R, K, W, Q or A; X 3E or H. Independent claims are also included for the following: (1) cyclic, amidated, acetylated, sulfated, phosphorylated, glycosylated and oxidized derivatives and fragments of (I), with similar biological activity; (2) methods for preparing (I), their derivatives or fragments; and (3) nucleic acid (II) that encodes one or more of (I), their derivatives or fragments. ACTIVITY : Antibacterial; antiinfertility; contraceptive. The peptide designated hBD17 TPGGTQRCWNLYGKCRYRCSKKERVYVYCINNKMCCVKPKYQPKERWWPF was positive in a radial diffusion test against Escherichia coli, Staphylococcus carnosusand Saccharomyces cerevisiae, and against S. carnosushad MIC below 25 Microg/ml. MECHANISM OF ACTION : Peptide therapy.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10033505.5 | 2000-07-11 | ||
| DE10033505 | 2000-07-11 | ||
| PCT/EP2001/007973 WO2002004487A2 (en) | 2000-07-11 | 2001-07-11 | Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001289641A1 true AU2001289641A1 (en) | 2002-01-21 |
Family
ID=7648436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001289641A Abandoned AU2001289641A1 (en) | 2000-07-11 | 2001-07-11 | Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20040116652A1 (en) |
| EP (2) | EP1887015A3 (en) |
| JP (1) | JP2004504017A (en) |
| AT (1) | ATE373091T1 (en) |
| AU (1) | AU2001289641A1 (en) |
| CA (1) | CA2427066A1 (en) |
| DE (1) | DE50113010D1 (en) |
| DK (1) | DK1299541T3 (en) |
| ES (1) | ES2197840T3 (en) |
| PT (1) | PT1299541E (en) |
| WO (1) | WO2002004487A2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576755B1 (en) | 1997-09-10 | 2003-06-10 | Zymogenetics, Inc. | Beta-defensins |
| EP1878794A3 (en) * | 1999-11-30 | 2008-01-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US6809181B2 (en) | 2000-06-01 | 2004-10-26 | University Of Iowa Research Foundation | Human beta-defensin-3 (HBD-3), a highly cationic beta-defensin antimicrobial peptide |
| AU2002227925A1 (en) * | 2000-11-14 | 2002-05-27 | Ipf Pharmaceuticals Gmbh | Human beta-defensin-3 |
| NZ540506A (en) * | 2002-12-19 | 2008-09-26 | Yitzchak Hillman | Disease treatment via antimicrobial peptide inhibitors |
| GB0300718D0 (en) | 2003-01-13 | 2003-02-12 | Ares Trading Sa | Proteins |
| FR2879203A1 (en) * | 2004-12-09 | 2006-06-16 | Univ Rennes I Etablissement Pu | ANTIMICROBIAL PEPTIDES, POLYPEPTIDES COMPRISING SAID PEPTIDES, PROCESSES FOR PREPARING THEM, GENES ENCODING THE SAME, VECTORS, PROCESSED ORGANISMS AND COMPOSITIONS CONTAINING SAME |
| US8202835B2 (en) | 2005-06-17 | 2012-06-19 | Yitzchak Hillman | Disease treatment via antimicrobial peptides or their inhibitors |
| US9044438B2 (en) | 2005-06-17 | 2015-06-02 | Yitzchak Hillman | Disease treatment via antimicrobial peptides or their inhibitors |
| GB0514482D0 (en) * | 2005-07-14 | 2005-08-17 | Ares Trading Sa | Protein |
| CN102198264B (en) * | 2010-03-23 | 2013-10-09 | 中国科学院上海生命科学研究院 | Rat epididymis-specific antimicrobial peptide β-defensin 15 and its application |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999013080A1 (en) * | 1997-09-10 | 1999-03-18 | Zymogenetics, Inc. | Beta-defensins |
| US6783961B1 (en) * | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| AU2668400A (en) * | 1999-02-01 | 2000-08-25 | Schering Aktiengesellschaft | Human antibiotic proteins |
| AU3086301A (en) * | 2000-01-05 | 2001-07-16 | Emory University | Epididymal antimicrobial peptides |
-
2001
- 2001-07-11 PT PT01969365T patent/PT1299541E/en unknown
- 2001-07-11 CA CA002427066A patent/CA2427066A1/en not_active Abandoned
- 2001-07-11 EP EP07116049A patent/EP1887015A3/en not_active Withdrawn
- 2001-07-11 AU AU2001289641A patent/AU2001289641A1/en not_active Abandoned
- 2001-07-11 ES ES01969365T patent/ES2197840T3/en not_active Expired - Lifetime
- 2001-07-11 AT AT01969365T patent/ATE373091T1/en not_active IP Right Cessation
- 2001-07-11 DE DE50113010T patent/DE50113010D1/en not_active Expired - Fee Related
- 2001-07-11 WO PCT/EP2001/007973 patent/WO2002004487A2/en not_active Ceased
- 2001-07-11 US US10/332,765 patent/US20040116652A1/en not_active Abandoned
- 2001-07-11 EP EP01969365A patent/EP1299541B1/en not_active Expired - Lifetime
- 2001-07-11 JP JP2002509350A patent/JP2004504017A/en not_active Abandoned
- 2001-07-11 DK DK01969365T patent/DK1299541T3/en active
-
2007
- 2007-04-27 US US11/790,770 patent/US20090124541A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090124541A1 (en) | 2009-05-14 |
| EP1887015A2 (en) | 2008-02-13 |
| EP1299541A2 (en) | 2003-04-09 |
| WO2002004487A2 (en) | 2002-01-17 |
| PT1299541E (en) | 2007-10-01 |
| EP1887015A3 (en) | 2008-05-07 |
| EP1299541B1 (en) | 2007-09-12 |
| ATE373091T1 (en) | 2007-09-15 |
| DE50113010D1 (en) | 2007-10-25 |
| CA2427066A1 (en) | 2003-02-24 |
| ES2197840T3 (en) | 2008-03-16 |
| WO2002004487A3 (en) | 2002-09-19 |
| US20040116652A1 (en) | 2004-06-17 |
| DK1299541T3 (en) | 2008-01-21 |
| ES2197840T1 (en) | 2004-01-16 |
| JP2004504017A (en) | 2004-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2032059C (en) | Wound treatment employing biologically active peptides | |
| EP2266595A3 (en) | Treatment of infections and other disorders | |
| AU2001289641A1 (en) | Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses | |
| RU94006023A (en) | Physiologically active composition on the base of lyophilized, modified by polyalkylene oxide complexes of protein and peptide with cyclodextrin and method for its production | |
| DK1025124T3 (en) | Human interferon-alpha analogs with low toxicity | |
| ATE108662T1 (en) | ANTIMICROBIAL PEPTIDES, COMPOSITIONS CONTAINING SAME AND USES THEREOF. | |
| EP1319023B8 (en) | An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof | |
| WO2004024925A8 (en) | Collectin-complement activating protein chimeras | |
| ATE400294T1 (en) | NEW ANTIMICROBIAL POLYPEPTIDES AND METHODS FOR USE THEREOF. | |
| Schrimsher et al. | Characterization of human and mouse granulocyte-macrophage-colony-stimulating factors derived from Escherichia coli | |
| WO2002096467A3 (en) | Pharmaceutical use for secreted bacterial effector proteins | |
| AU7791398A (en) | Antimicrobial peptides derived from ubiquicidine | |
| JPH07502979A (en) | Prevention and treatment of harmful conditions in the oral cavity using bioactive peptides | |
| JPH07501820A (en) | Compositions and treatments with bioactive peptides and chelating agents | |
| WO2003051383A3 (en) | Use of hmgb proteins and nucleic acids that code therefor | |
| WO2001034640A3 (en) | Peptide (virip) which inhibits a circulating virus in humans and the use thereof | |
| Iwahori et al. | Synthesis of reversed magainin 2 analogs enhanced antibacterial activity | |
| EP0533795A1 (en) | Composition of and treatment with biologically active peptides having d-amino acid residues | |
| CA2290739A1 (en) | New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy | |
| CA2459811A1 (en) | Modified peptides and their use for the treatment of autoimmune diseases | |
| ES2188653T3 (en) | VARIATIONS OF HUMAN DNASA I. | |
| WO2003064446A3 (en) | Plasma protein-binding peptides from bacterial curli | |
| WO2004000870A3 (en) | Two synthetic peptides for treatment and prevention of cancers | |
| WO2002100897A3 (en) | Brca1/acc alpha molecular complexes, diagnostic and therapeutic applications | |
| WO1998056810A3 (en) | Lus-1 human protein, its production and use |